# US 2023/0144608 A1 · Cleavable linkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144608 A1
- Document ID: US20230144608A1
- Status: Published application
- Kind: A1
- Application number: 17/932,057
- Filed: 2022-09-14
- Published: 2023-05-11
- Earliest claimed: 2021-09-14
- Assignees: Xilio Development, Inc.
- Applicants: Xilio Development, Inc.
- Inventors: Dheeraj Singh Tomar; Magali Pederzoli-Ribeil; Giselle Marcelline Knudsen
- Web page: https://patentgrep.com/patent/US20230144608A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/7155: {for interleukins [IL]}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/50: containing protease site
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses proteolytically cleavable peptide (CP) substrates, polypeptides, polypeptide constructs and prodrug constructs comprising the proteolytically cleavable peptides (e.g., cytokine prodrugs), and methods of use of the same.

## Claims

### Claim 1

A polypeptide comprising a proteolytically cleavable peptide linker, wherein the linker comprises a proteolytically cleavable peptide (CP) consisting of the amino acid sequence PVSLRSGS (SEQ ID NO:1) or GMPKDLYHAS (SEQ ID NO:2), or RPLALWRS (SEQ ID NO:3), or TQKPLGLS (SEQ ID NO:4), or APAGLIVPYN (SEQ ID NO:5), or PANLVAPDP (SEQ ID NO:6), or IVGRPRHQGV (SEQ ID NO:7), or RSKYLATA (SEQ ID NO:8).

### Claim 2

A polypeptide construct comprising a proteolytically cleavable peptide linker, wherein the linker comprises a proteolytically cleavable peptide (CP) consisting of the amino acid sequence PVSLRSGS (SEQ ID NO:1) or GMPKDLYHAS (SEQ ID NO:2), or RPLALWRS (SEQ ID NO:3), or TQKPLGLS (SEQ ID NO:4), or APAGLIVPYN (SEQ ID NO:5), or PANLVAPDP (SEQ ID NO:6), or IVGRPRHQGV (SEQ ID NO:7), or RSKYLATA (SEQ ID NO:8).

### Claim at position 3

3-10. (canceled)

### Claim 11 (depends on 2)

The polypeptide construct according to claim 2, wherein the proteolytically cleavable peptide linker is from 8 to 25 amino acids in length.

### Claim 12

(canceled)

### Claim 13 (depends on 2)

The polypeptide construct according claim 2, wherein the polypeptide construct comprises a therapeutic moiety.

### Claim 14 (depends on 2)

The polypeptide construct claim 2, wherein the proteolytically cleavable peptide linker is located within the construct between a therapeutic moiety and a carrier moiety.

### Claim at position 8

15-18. (canceled)

### Claim 19 (depends on 2)

The polypeptide construct according claim 2, wherein the polypeptide construct is a prodrug comprising a masking moiety, wherein the masking moiety comprises a domain of the extracellular domain of the cytokine receptor.

### Claim 20 (depends on 2)

The polypeptide construct according to claim 2, further comprising a masking moiety, a half-life extension moiety or a targeting moiety.

### Claim at position 11

21-23. (canceled)

### Claim 24 (depends on 1)

A masked cytokine comprising:
a) a first polypeptide chain comprising a masking moiety linked to a first half-life extension moiety via a first linker; and
b) a second polypeptide chain comprising a cytokine moiety thereof linked to a second half-life extension moiety via a second linker,
wherein the first half-life extension moiety is associated with the second half-life extension moiety, and
wherein at least the first linker or the second linker comprises the polypeptide of claim 1.

### Claim 25 (depends on 24)

The masked cytokine according to claim 24, wherein the second linker is the proteolytically cleavable linker and the first linker is a non-cleavable linker.

### Claim 26 (depends on 24)

The masked cytokine according to claim 24, wherein the first linker is the proteolytically cleavable linker and the second linker is a non-cleavable linker.

### Claim at position 15

27-34. (canceled)

### Claim 35

A targeted cytokine comprising:
a) a targeting moiety;
b) a cytokine or a fragment thereof;
c) a masking moiety; and
d) an Fc domain comprising a first Fc polypeptide linked to the cytokine or a fragment thereof through a first linker and a second Fc polypeptide linked to the masking moiety through a second linker, wherein the first or the second linker is a cleavable linker such that the masking moiety releases the cytokine or a fragment thereof upon cleavage;
wherein the targeting moiety is linked to the Fc domain through one or both of the first and second Fc polypeptides; and
wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence PVSLRSGS (SEQ ID NO:1), or GMPKDLYHAS (SEQ ID NO:2), or RPLALWRS (SEQ ID NO:3), or TQKPLGLS (SEQ ID NO:4), or APAGLIVPYN (SEQ ID NO:5), or PANLVAPDP (SEQ ID NO:6), or IVGRPRHQGV (SEQ ID NO:7), or RSKYLATA (SEQ ID NO:8).

### Claim 36 (depends on 35)

The targeted cytokine of claim 35, wherein the second linker is the proteolytically cleavable linker and the first linker is a non-cleavable linker, or wherein the first linker is the proteolytically cleavable linker and the second linker is a non-cleavable linker.

### Claim at position 18

37-45. (canceled)

### Claim 46 (depends on 35)

The targeted cytokine according claim 35, wherein the targeting moiety is an antibody or an antigen binding domain thereof.

### Claim 47 (depends on 1)

A cleavage product obtainable by proteolytic cleavage of the proteolytically cleavable linker in a polypeptide or polypeptide construct according to claim 1.

### Claim 48 (depends on 1)

A nucleic acid encoding a polypeptide according to claim 1.

### Claim 49 (depends on 48)

A vector comprising a nucleic acid according to claim 48.

### Claim 50 (depends on 49)

A host cell comprising a vector according to claim 49.

### Claim 51

(canceled)

### Claim 52 (depends on 2)

A pharmaceutical composition comprising the polypeptide construct according to claim 2, and a pharmaceutically acceptable carrier.

### Claim 53 (depends on 52)

A kit comprising a pharmaceutical composition according to claim 52.

### Claim 54

(canceled)

### Claim 55 (depends on 13)

A method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a polypeptide construct according to claim 13.

### Claim at position 29

56-57. (canceled)
